Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Invested Capital (2025)

Historic Return on Invested Capital for Keros Therapeutics (KROS) over the last 5 years, with Q3 2025 value amounting to 0.06%.

  • Keros Therapeutics' Return on Invested Capital changed N/A to 0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year change of. This contributed to the annual value of 0.47% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Return on Invested Capital is 0.06%.
  • In the past 5 years, Keros Therapeutics' Return on Invested Capital registered a high of 0.06% during Q3 2025, and its lowest value of 0.4% during Q3 2022.
  • For the 4-year period, Keros Therapeutics' Return on Invested Capital averaged around 0.22%, with its median value being 0.25% (2021).
  • Examining YoY changes over the last 5 years, Keros Therapeutics' Return on Invested Capital showed a top increase of 2200bps in 2021 and a maximum decrease of -10200bps in 2021.
  • Quarter analysis of 4 years shows Keros Therapeutics' Return on Invested Capital stood at 0.25% in 2021, then plummeted by -57bps to 0.4% in 2022, then grew by 4bps to 0.38% in 2024, then skyrocketed by 115bps to 0.06% in 2025.
  • Its Return on Invested Capital was 0.06% in Q3 2025, compared to 0.0% in Q2 2025 and 0.0% in Q1 2025.